An interventional study of Virtual Health Coaching with Artificial Intelligence (DIACOACH) and Standard Diabetes Education in Type 2 Diabetes Mellitus (T2DM), sponsored by Hasanuddin University. Not yet recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Hasanuddin University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Diabetes Mellitus, Type 2 with a site in Indonesia — 9 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Indonesia.
Among the 67 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, this one is the 11th largest by planned enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2025, is one of 26 with no phase, and was the 53rd registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →9 of the 67 studies in Diabetes Mellitus, Type 2 with a site in Indonesia are open now. Recruiting first, the newest first:
Universitas Sriwijaya · Sites in Indonesia
Ages 30–65
Novo Nordisk A/S · Sites in Indonesia, Malaysia, Philippines and 1 more country
Ages 40–70
Indonesia University · Sites in Indonesia
Ages 35–59
Boryung Pharmaceutical Co., Ltd · Sites in Indonesia, Korea, Republic of
Ages 19+
Indonesia University · Sites in Indonesia
Ages 8–40 · Healthy volunteers
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 10 · Phase 4 8
First in 2003; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 206 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 53 interventional studies, 1,750 across the 14 observational. Of the 48 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 67 have an industry lead sponsor. The 10 most frequent:
Hasanuddin University is the lead sponsor of 71 studies on the registry; 6 are open to participants now.
Hasanuddin University has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetes Mellitus, Type 2 with a site in Indonesia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT07064486Phase 3BrightGene Bio-Medical Technology Co., Ltd.A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | 2027-04-30 |
| NCT07928661Universitas SriwijayaEffect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes | 2026-12 |
| NCT07532863Novo Nordisk A/SA Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants | 2027-03-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 67 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effectiveness of a virtual health coaching program based on artificial intelligence (AI) in improving blood sugar control among people with type 2 diabetes in primary health care settings in Jeneponto and Bantaeng, Indonesia. The intervention will be delivered through the DIACOACH application, which provides personalized coaching, lifestyle guidance, and self-care support. Participants will be randomly assigned to either the intervention group, receiving virtual health coaching for 12 weeks, or the control group, receiving standard diabetes education. Main outcomes include fasting blood sugar and HbA1c levels. Other outcomes include self-care adherence, dietary behavior, and quality of life. This trial seeks to provide evidence on whether AI-based virtual coaching is a practical and effective digital health solution to support diabetes self-management in community health settings with limited resources.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by elevated blood glucose levels due to impaired insulin production or insulin resistance. Globally, the prevalence of T2DM continues to rise, and in Indonesia the number of cases has surpassed 10 million, placing the country among the top seven worldwide for diabetes prevalence. Poor glycemic control leads to serious complications such as kidney disease, cardiovascular disorders, and neuropathy, which reduce patients' quality of life and increase health care costs. One of the main challenges in diabetes management is the low level of patient adherence to recommended lifestyle changes, including diet, physical activity, and regular monitoring. Patients often struggle to maintain long-term self-management because of limited access to continuous education, motivation, and personalized support in primary health care settings.
Digital health innovations, including virtual health coaching, have emerged as promising solutions to address these challenges. Virtual health coaching provides structured, ongoing support by using digital platforms to deliver education, reminders, and behavioral feedback. The integration of artificial intelligence (AI) into virtual coaching systems allows the intervention to be more adaptive and personalized, responding to the unique behaviors and needs of each participant. The DIACOACH application has been specifically developed to support diabetes self-management in Indonesia. It offers adaptive education modules, lifestyle modification reminders, diet and exercise monitoring, medication tracking, and a chatbot interface for personalized interaction. Early community service activities using DIACOACH have shown improvements in patient knowledge, motivation, and preliminary indicators of glycemic control such as fasting blood glucose and HbA1c levels. However, systematic research is required to evaluate its effectiveness in a controlled study, particularly in primary care contexts with limited resources.
This study is designed as a quasi-experimental trial with a non-equivalent control group design. Participants will be adults aged 30 to 56 years who have been diagnosed with T2DM for more than three months, are clinically stable, able to read, and have access to a smartphone or digital device. Individuals with type 1 diabetes, severe complications, ongoing steroid therapy, or those enrolled in other structured interventions will be excluded. Eligible participants will be recruited from primary health care centers (Puskesmas) in Jeneponto and Bantaeng, Indonesia. After baseline assessments, participants will be allocated to either the intervention group or the control group.
The intervention group will use the DIACOACH application for twelve weeks. Through this platform, participants will receive adaptive education tailored to their daily routines, reminders about diet and physical activity, and continuous encouragement to maintain self-care practices. The app integrates principles of Social Cognitive Theory and Self-Determination Theory to build self-efficacy and intrinsic motivation. The AI-based system provides feedback based on real-time data entered by participants, such as blood glucose values, diet logs, exercise activities, and medication adherence. The control group will continue with standard diabetes education typically offered at health centers, which usually consists of routine counseling sessions and printed health information.
Primary outcomes will include fasting blood glucose (FBG), HbA1c, and random blood glucose (RBG), measured at baseline and after the twelve-week intervention. Secondary outcomes will assess changes in dietary behavior, physical activity, adherence to self-care, satisfaction with the intervention, and overall quality of life. Data will be collected through laboratory tests, validated questionnaires, and digital records from the application. Quantitative data will be analyzed using appropriate statistical tests such as paired t-tests and analysis of variance to evaluate differences between groups and across time points. In addition, a qualitative component will be conducted by interviewing selected participants from the intervention group to explore their perceptions, experiences, barriers, and facilitators in using AI-based virtual coaching for diabetes self-management.
The study is expected to provide comprehensive evidence on the feasibility, acceptability, and effectiveness of AI-based virtual health coaching in primary health care. As a preliminary study, it will serve to validate the DIACOACH platform and assess its potential impact on clinical outcomes as well as patient engagement. If the intervention is found to be effective, it may offer a scalable and low-cost strategy to improve diabetes management in Indonesia, particularly in underserved and resource-constrained communities. Furthermore, this research could contribute to the integration of digital health innovations into the national primary health care system and support ongoing initiatives to reduce the burden of diabetes and its complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with Type 2 Diabetes Mellitus for more than 3 months
Age between 30 and 56 years
Able to read and understand instructions
Have access to a digital device (smartphone or similar)
In stable clinical condition
Exclusion Criteria:
Diagnosed with Type 1 Diabetes Mellitus
Patients with severe complications (e.g., advanced nephropathy, retinopathy, cardiovascular disease)
Patients currently undergoing other structured interventions
Patients on long-term therapy
Patients without access to a digital device
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive a 12-week virtual health coaching program through the DIACOACH application. The app provides adaptive education, reminders, self-care monitoring, and AI-based personalized feedback to support glycemic control.
Behavioral: Virtual Health Coaching with Artificial Intelligence (DIACOACH)
Participants in this group will receive standard diabetes education provided by primary health care centers, including routine counseling sessions and printed health information.
Behavioral: Standard Diabetes Education
Participants in the intervention group will receive a 12-week virtual health coaching program using the DIACOACH application. The program includes adaptive digital education on diet, physical activity, and medication adherence, personalized reminders, daily self-monitoring, and feedback powered by artificial intelligence. The intervention is designed to improve self-care adherence and glycemic control (FBG, HbA1c, RBG) among adults with type 2 diabetes mellitus in primary care settings.
Participants in the control group will receive standard diabetes education usually provided in primary health care centers. This includes routine counseling sessions, printed educational materials, and general advice on diet, physical activity, and medication adherence, without the use of the DIACOACH application.
Fasting Blood Glucose (FBG)
Change in fasting blood glucose (mg/dL) from baseline to post-intervention, measured using standardized laboratory methods
Time frame: Baseline and 12 weeks after intervention
Glycated Hemoglobin (HbA1c)
Change in HbA1c (%) from baseline to post-intervention, measured using standardized laboratory methods.
Time frame: Baseline and 12 weeks after intervention.
Self-care Adherence
Measured using the Summary of Diabetes Self-Care Activities (SDSCA) questionnaire. Higher scores indicate better adherence
Time frame: Baseline and 12 weeks after intervention.
Dietary Behavior
Changes in dietary behavior assessed using validated dietary recall questionnaires.
Time frame: Baseline and 12 weeks after intervention.
Physical Activity
Measured using the International Physical Activity Questionnaire (IPAQ), reported in MET-minutes/week.
Time frame: Baseline and 12 weeks after intervention.
Plan to share: Undecided — At this stage, the plan to share individual participant data (IPD) has not yet been determined. The decision will depend on institutional policies, ethical approvals, and participant consent. Data may be shared in the future upon request, following anonymization and appropriate agreements.
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Dec 2025, 3 months later.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 3 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hasanuddin University